海王生物(000078.SZ):擬將合計轉讓約26億元應收賬款
格隆匯1月3日丨海王生物(000078.SZ)公佈,公司於2021年5月28日召開的第八屆董事局第二十次會議審議通過了《關於轉讓子公司部分應收賬款的議案》,公司將子公司持有的合計約21億元應收賬款轉讓給長春感通以及金伊醫療。在公司與長春感通以及金伊醫療簽訂應收賬款轉讓協議後,建立起了良好的合作關係。截至目前,公司已經收到合同約定的全部應收賬款轉讓對價款。
基於前次合作的基礎,同時因受疫情持續影響,客户回款速度有所放緩,公司應收賬款週轉天數持續增加。為了繼續盤活下屬子公司應收賬款,及時回收流動資金,改善財務狀況,公司擬再次與長春感通以及金伊醫療展開合作。
公司(或公司全資子公司深圳市海王銀河醫藥投資有限公司)將子公司持有的應收賬款約13億元轉讓給長春感通,將子公司持有的應收賬款約13億元轉讓給金伊醫療。具體出售應收賬款明細及轉讓費用將根據約定執行。
應收賬款客户主要為國內醫療機構,以二級以上公立醫院為主。該部分客户資信較好,回款有保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.